文献速递肝病消化道出血消化内镜

经颈静脉肝内门体分流术治疗无肝硬化慢性肠系膜静脉血栓及肝外门静脉梗阻

TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy.
PubMed 文献 · Hepatology · 2021-07-08

TIPS技术成功率为100%,6个月随访时87%(26/30)患者症状改善,12例(31%)发生TIPS血栓形成;36个月时无原发性TIPS血栓形成率为63%,二次干预后总通畅率提高至81%。结论认为TIPS技术可行且不损害肝功能,多数患者获益,但需优化抗凝时机以提高通畅率。

要点

  • TIPS在无肝硬化慢性EHPVO及肠系膜静脉血栓患者中技术可行,技术成功率100%。
  • 6个月随访87%患者症状改善,31%发生TIPS血栓形成。
  • 36个月无原发性TIPS血栓形成率63%,二次干预后总通畅率81%。

核心结论

  • TIPS在无肝硬化慢性EHPVO伴海绵样变和肠系膜静脉血栓患者中技术可行,不 adverse 影响肝功能,多数患者获得主观和客观获益,但需改善通畅率并优化辅助抗凝时机。

主要发现

  • 所有患者均存在海绵样变,TIPS技术成功率为100%(采用脾静脉、肠系膜静脉和经肝途径)。
  • 6个月随访时30例中26例(87%)症状改善。
  • 12例(31%)发生TIPS血栓形成,无显著长期实验室不良事件或死亡。
  • 36个月时无原发性TIPS血栓形成率为63%,二次干预后总通畅率提高至81%。

临床怎么用

  • 对于无肝硬化慢性EHPVO伴海绵样变和肠系膜静脉血栓且标准治疗无效的成人患者,TIPS可作为可行治疗选择,但需关注血栓形成风险并计划二次干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Extrahepatic portal vein occlusion (EHPVO) from portal vein thrombosis is a rare condition associated with substantial morbidity and mortality. The purpose of this study is to investigate the efficacy of transjugular intrahepatic portosystemic shunts (TIPS) for the treatment of chronic EHPVO, cavernomatosis, and mesenteric venous thrombosis in adults without cirrhosis who are refractory to standard-of-care therapy. APPROACH AND RESULTS: Thirty-nine patients with chronic EHPVO received TIPS. Laboratory parameters and follow-up were assessed at 1, 3, 6, 12, and 24 months, and every 6 months thereafter. Two hepatologists adjudicated symptom improvement attributable to mesenteric thrombosis and EHPVO before/after TIPS. Kaplan-Meier was used to assess primary and overall TIPS patency, assessing procedural success. Adverse events, radiation exposure, hospital length-of-stay and patency were recorded. Cavernoma was present in 100%, with TIPS being successful in all cases using splenic, mesenteric, and transhepatic approaches. Symptom improvement was noted in 26 of 30 (87%) at 6-month follow-up. Twelve patients (31%) experienced TIPS thrombosis. There were no significant long-term laboratory adverse events or deaths. At 36 months, freedom from primary TIPS thrombosis was 63%; following secondary interventions, overall patency was increased to 81%. CONCLUSIONS: TIPS in chronic, noncirrhotic EHPVO with cavernomas and mesenteric venous thrombosis is technically feasible and does not adversely affect liver function. Most patients demonstrate subjective and objective benefit from TIPS. Improvement in patency rates are needed with proper timing of adjuvant anticoagulation.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Knight GM, Clark J, Boike JR, et al. TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy. Hepatology. 2021. PMID: 34021505. doi:10.1002/hep.31915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。